FISEVIER

Contents lists available at ScienceDirect

Progress in Neurobiology

journal homepage: www.elsevier.com/locate/pneurobio



Autophagy and apoptosis dysfunction in neurodegenerative disorders



Saeid Ghavami ^{a,b,c,1}, Shahla Shojaei ^{d,1}, Behzad Yeganeh ^{b,l,1}, Sudharsana R. Ande ^e, Jaganmohan R. Jangamreddy ^f, Maryam Mehrpour ^g, Jonas Christoffersson ^f, Wiem Chaabane ^{f,h}, Adel Rezaei Moghadam ⁱ, Hessam H. Kashani ^{a,b}, Mohammad Hashemi ^{j,k}, Ali A. Owji ^{d,2,**}, Marek J. Łos ^{f,2,*}

- ^a Department of Human Anatomy and Cell Science, University of Manitoba, Winnipeg, Canada
- ^b Manitoba Institute of Child Health, Department of Physiology, University of Manitoba, Winnipeg, Canada
- ^c St. Boniface Research Centre, University of Manitoba, Winnipeg, Canada
- ^d Department of Biochemistry, Recombinant Protein Laboratory, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran
- ^e Department of Internal Medicine, University of Manitoba, Winnipeg, Canada
- Department of Clinical and Experimental Medicine (IKE), Integrative Regenerative Medicine Center (IGEN), Division of Cell Biology, Linkoping University, Linkoping, Sweden
- g INSERM U845, Research Center "Growth & Signaling" Paris Descartes University Medical School, France
- ^h Department of Biology, Faculty of Sciences, Tunis University, Tunis, Tunisia
- ¹ Young Researchers Club, Ardabil Branch, Islamic Azad University, Ardabil, Iran
- ^jDepartment of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
- ^k Cellular and Molecular Biology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
- ¹Hospital for Sick Children Research Institute, Department of Physiology and Experimental Medicine, University of Toronto, Canada

ARTICLE INFO

Article history: Received 30 December 2012 Received in revised form 8 October 2013 Accepted 15 October 2013 Available online 6 November 2013

Keywords: Mitochondria dysfunction Porteopathies Resveratrol RSVA314 RSVA405 Trehalose

ABSTRACT

Autophagy and apoptosis are basic physiologic processes contributing to the maintenance of cellular homeostasis. Autophagy encompasses pathways that target long-lived cytosolic proteins and damaged organelles. It involves a sequential set of events including double membrane formation, elongation, vesicle maturation and finally delivery of the targeted materials to the lysosome. Apoptotic cell death is best described through its morphology. It is characterized by cell rounding, membrane blebbing, cytoskeletal collapse, cytoplasmic condensation, and fragmentation, nuclear pyknosis, chromatin condensation/fragmentation, and formation of membrane-enveloped apoptotic bodies, that are rapidly phagocytosed by macrophages or neighboring cells. Neurodegenerative disorders are becoming increasingly prevalent, especially in the Western societies, with larger percentage of members living to an older age. They have to be seen not only as a health problem, but since they are care-intensive, they also carry a significant economic burden. Deregulation of autophagy plays a pivotal role in the etiology and/or progress of many of these diseases. Herein, we briefly review the latest findings that indicate the involvement of autophagy in neurodegenerative diseases. We provide a brief introduction to autophagy and apoptosis pathways focusing on the role of mitochondria and lysosomes. We then briefly highlight pathophysiology of common neurodegenerative disorders like Alzheimer's diseases, Parkinson's disease, Huntington's disease and Amyotrophic lateral sclerosis. Then, we describe functions of autophagy and

Abbreviations: AMBRA, activating molecule in Beclin-1-regulated autophagy; AD, Alzheimer's diseases; AMPA, α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; A β , amyloid-beta; α -syn, alpha-synuclein; ALS, amyotrophic lateral sclerosis; APP, amyloid beta precursor protein; AMPK, AMP-activated protein kinase; Apo-E, apolipo-protein E; AIF, apoptosis-inducing factor; ATG, autphagy related genes; LC3, autophagosome-associated light chain 3; BDNF, brain-derived neurotrophic factor; CMA, chaperon-mediated autophagy; ER, endoplasmic reticulum; ESCRT, endosomal sorting complexes required for transport; HEK293, human embryonic kidney 293 cells; HD, Huntington's disease; Htt, Huntingtin protein; HIP-1, Huntingtin interacting protein; lnsP(6)Ks, inositol hexakisphosphate kinases; LAMP, lysosomal associated membrane proteins; MAP15, microtubule-associated protein 15; LRPPRC, mitochondrion-associated leucine-rich PPR-motif containing protein; mPTP, mitochondrial permeability transition pore; mTOR, mammalian target of rapamycin; mHtt, mutant Huntingtin protein; NMDA, N-methyl-p-aspartate; NCCD, nomenclature committee on cell death; PD, Parkinson's disease; PON 1–3, paraxonase enzymes; pQ, poly-glutamine; PCD, programmed cell death; PINK-1, PTEN-induced putative kinase 1; RCAN-1, regulator of calcineurin-1; RUBICON, RUN domain and cysteine rich domain containing; TDP-43-kDa, TAR DNA-binding protein 43 kDa; p53, tumor protein 53; UPS, ubiquitin-proteasome system; UVRAG, ultra-violet radiation resistance-associated gene; VCP, valosin-containing protein; XBP-1, X-box binding protein-1.

- * Corresponding author. Tel.: +46 101032787.
- ** Corresponding author.
- E-mail addresses: aaowji@yahoo.com (A.A. Owji), mjelos@gmail.com (M.J. Łos).
- ¹ All three authors have equal first authorship.
- ² Both authors have equal senior authorship.

apoptosis in brain homeostasis, especially in the context of the aforementioned disorders. Finally, we discuss different ways that autophagy and apoptosis modulation may be employed for therapeutic intervention during the maintenance of neurodegenerative disorders.

© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.

Contents

| 1. | Introduction | 25 |
|-----|--|----|
| 2. | Cell death | 26 |
| 3. | Autophagy | 26 |
| 4. | Autophagy machinery and its regulation | 26 |
| 5. | Role of mitochondria in autophagy | 27 |
| 6. | Autophagy and brain homeostasis | 28 |
| 7. | Apoptosis and its regulation | 29 |
| 8. | Importance of apoptosis in central- and peripheral nerve system | 30 |
| 9. | Alzheimer's disease | 30 |
| 10. | Parkinson's disease | 31 |
| 11. | Huntington's disease | 32 |
| 12. | Amyotrophic lateral sclerosis | 32 |
| 13. | Neuroinflammation in neurodegenerative diseases | 32 |
| | 13.1. General dynamics of neuroinflammation in neurodegenerative diseases | 32 |
| | 13.2. Alzheimer's diseases and neuroinflammation | 32 |
| | 13.3. Parkinson's disease and neuroinflammation | 33 |
| | 13.4. Amyotrophic lateral sclerosis and neuroinflammation | 33 |
| 14. | Autpophagy hyperactivation or failure associated with neuronal cell death | 33 |
| 15. | Autophagy and neurodegenerative disease | |
| | 15.1. Alzheimer's diseases – disturbed autophagy as a contributing factor | 35 |
| | 15.2. Parkinson's disease – autophagy as possible protective factor | 35 |
| | 15.3. Huntington's disease – potential pro-survival effect of autophagy | |
| | 15.4. Convoluted role of autophagy in the etiology and progression of amyotrophic lateral sclerosis | 36 |
| | 15.5. Autophagy and neuroinflammation | 37 |
| 16. | Apoptosis and neurodegenerative disease | 37 |
| | 16.1. Apoptosis in Alzheimer's diseases | 37 |
| | 16.2. The role of apoptosis in the etiology and progression of Parkinson's disease | 37 |
| | 16.3. Excitotoxicity-triggered apoptosis and other effects of mutated huntingtin protein in Huntington's disease | |
| | 16.4. Amyotrophic lateral sclerosis and the role of apoptosis in the onset and progression of the disease | 38 |
| 17. | Connection between age-related neurodegenerative disorders and cell aging/cell senescence | 39 |
| 18. | The potential of autophagy- and apoptosis modulation as a treatment strategy in neurodegenerative diseases | |
| | 18.1. Autophagy modulation and Huntington's diseases treatment strategies | 39 |
| | 18.2. Alzheimer's diseases – autophagy modulation as therapy approach | 40 |
| | 18.3. Parkinson's disease – therapeutic effect of autophagy | 41 |
| | 18.4. Apoptosis modulation and neurodegenerative diseases treatment strategy | |
| 19. | Closing remarks | 42 |
| | Acknowledgements | 42 |
| | References | 42 |
| | | |

1. Introduction

In proteopathies, certain proteins become structurally abnormal, accumulate in cells and tissues, and disrupt their function (Luheshi et al., 2008). Proteopathies include diverse neurodegenerative disorders such as Alzheimer's diseases (AD), Parkinson's disease (PD), Huntington's disease (HD) and Amyotrophic lateral sclerosis (ALS) in which abnormally assembled proteins appear to play a central role (Xilouri and Stefanis, 2010). Abnormal or misfolded proteins, when aggregated in cytoplasmic, nuclear and extracellular inclusions cause organelle damage and synaptic dysfunction in the nervous system (Walker and LeVine, 2000). Two elimination pathways are currently known for damaged cellular components. Both of them control the quality of cellular components and maintain cell homeostasis. These are, the ubiquitin-proteasome system (UPS) that degrades short-lived proteins in the cytoplasm and nucleus, and the autophagylysosome pathway (ALP) which digests long-lived proteins and abnormal organelles just in the cytoplasm (Nijholt et al., 2011). The proper function and balance in the action of these two systems are especially important in neurons and other long-lived cells. Hence, their dysfunction contributes to pathogeneses of neurodegenerative diseases (Ciechanover, 2005; Rubinsztein, 2006).

Besides autophagy disturbances, deregulation of apoptosis is associated with a long list of pathologies, including neurodegenerative disorders (Agostini et al., 2011). After multi-cellular organisms reach adulthood, apoptotic processes remove old and damaged cells to maintain tissue homeostasis without harming adjacent cells (Hellwig et al., 2011). With the exception of postmitotic cells such as differentiated neurons and muscle cells, which are usually highly apoptosis-resistant, the majority of other cells in the body is regularly renewed, particularly within epithelia, endothelia and the blood (Hellwig et al., 2011). Hence, recent reports have emphasized the importance of apoptosis in proteopathies diseases (Agostini et al., 2011; Hellwig et al., 2011).

Below, we briefly introduce autophagy and apoptosis pathways focusing on the role of mitochondria and lysosomes in both pathways, followed by autophagy and apoptosis function in brain homeostasis. Furthermore, some of the most common neurodegenerative diseases will be described, then, we explain characteristic

Download English Version:

https://daneshyari.com/en/article/6286524

Download Persian Version:

https://daneshyari.com/article/6286524

Daneshyari.com